drugset / Trial / NCT01359254

Cord Blood Transplantation for Patients With Cancer

NCT01359254

Phase 2 Terminated 1 enrolled University of Chicago
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.

Timeline

Start
2010-04
Primary completion
2011-09
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule
Subject Melphalan Small molecule
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic
Background Fludarabine Small molecule Intravenous

Indications